Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $135000.0.

  • Traws Pharma's Share-based Compensation fell 6064.14% to $135000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $735000.0, marking a year-over-year decrease of 4704.61%. This contributed to the annual value of $1.4 million for FY2024, which is 684.09% up from last year.
  • Per Traws Pharma's latest filing, its Share-based Compensation stood at $135000.0 for Q3 2025, which was down 6064.14% from $105000.0 recorded in Q2 2025.
  • In the past 5 years, Traws Pharma's Share-based Compensation ranged from a high of $380000.0 in Q2 2024 and a low of $60000.0 during Q2 2021
  • For the 5-year period, Traws Pharma's Share-based Compensation averaged around $253473.7, with its median value being $289000.0 (2022).
  • In the last 5 years, Traws Pharma's Share-based Compensation skyrocketed by 35538.46% in 2022 and then crashed by 7236.84% in 2025.
  • Traws Pharma's Share-based Compensation (Quarter) stood at $261000.0 in 2021, then grew by 26.44% to $330000.0 in 2022, then rose by 0.61% to $332000.0 in 2023, then grew by 0.6% to $334000.0 in 2024, then tumbled by 59.58% to $135000.0 in 2025.
  • Its Share-based Compensation was $135000.0 in Q3 2025, compared to $105000.0 in Q2 2025 and $161000.0 in Q1 2025.